SEARCH

SEARCH BY CITATION

Keywords:

  • in vitro fertilisation;
  • infertility;
  • intracytoplasmic sperm injection;
  • male;
  • semen analysis

Abstract

  1. Top of page
  2. Abstract
  3. Introduction
  4. Epidemiology of male infertility
  5. Regulation of spermatogenesis
  6. Causes of male infertility
  7. Clinical management
  8. Investigations
  9. Treatment options
  10. Ethical issues
  11. Conclusion
  12. References

Key content

  • Male factors alone account for up to 30% of subfertile couples undergoing in vitro fertilisation.
  • Male infertility may be due to problems with sperm production or transport and also sexual dysfunction. The underlying cause in most cases is idiopathic.
  • Modifiable lifestyle factors can have an impact on male fertility, but medical treatments have a limited value in enhancing semen quality. Most treatments are based on assisted fertilisation techniques, rather than treatment of the underlying cause.
  • The number and quality of sperm that can be recovered, either from the ejaculate or surgically, determines the available options for assisted conception.
  • Intracytoplasmic sperm injection (ICSI) is considered relatively safe; however, because of the ability to bypass natural barriers to conception, there are concerns regarding its potential to transmit genetic defects.

Learning objectives

  • To review appropriate practice in the assessment and investigation of the infertile male.
  • To critically appraise the currently available investigations for male fertility.
  • To summarise the treatment options for subfertile men.

Ethical issues

  • Does ICSI propagate genetic causes of male infertility?
  • Could there ever be a role for the use of artificial sperm in assisted reproduction?

Introduction

  1. Top of page
  2. Abstract
  3. Introduction
  4. Epidemiology of male infertility
  5. Regulation of spermatogenesis
  6. Causes of male infertility
  7. Clinical management
  8. Investigations
  9. Treatment options
  10. Ethical issues
  11. Conclusion
  12. References

It is estimated that one in seven couples in the UK experience some difficulty conceiving at some point in their reproductive life.[1] Sixteen percent of couples will fail to conceive after 1 year of trying.[1] A male factor alone is thought to contribute in up to 30% of these cases, with a combination of male and female factors affecting up to 40% of all infertile couples undergoing assisted reproduction.[2-4]

‘Normal’ reference values for semen quality were first published by McLeod[5] in 1951. For several decades male infertility was considered an idiopathic and incurable condition, however, with advances in assisted reproductive technologies, effective treatments have now been developed and research into factors affecting sperm quality is increasing.

Epidemiology of male infertility

  1. Top of page
  2. Abstract
  3. Introduction
  4. Epidemiology of male infertility
  5. Regulation of spermatogenesis
  6. Causes of male infertility
  7. Clinical management
  8. Investigations
  9. Treatment options
  10. Ethical issues
  11. Conclusion
  12. References

It is difficult to estimate the prevalence of male infertility in the general population, as reported fertility rates are dependent upon numerous factors, such as coital frequency, and do not necessarily reflect biological fertility. Studies in the early 1990s suggested a possible decline in semen quality,[6] however, subsequent reports suggest that this finding is not universal.[7] Demographic data on UK fertility rates provide evidence to suggest that male infertility is increasing.[8] This, however, may be the result of increasing publicity of available treatments and thus reflect an increasing willingness of couples to seek advice and treatment. Long-term data from the Human Fertilisation and Embryology Authority (HFEA)[9] analysing male factors as a cause for referral to fertility centres, has shown that the percentage of infertility attributable to male factors appears to have increased from 27.6% in 2000 to 32.5% in 2006, but since then it averages at approximately 30%.[4] The evidence that sperm counts may be declining has been linked to the theory of testicular dysgenesis syndrome (TDS), which comprises a developmental disorder with increased rates of testicular cancer, undescended testes and congenital malformations.[10] This may be due to environmental factors. However, the validity of this theory has recently been questioned.[11]

Box 1. Main causes of male factor infertility

  • Pretesticular:
    • Hypothalamic disease
      • - Gonadotrophin deficiency (Kallman syndrome)
    • Pituitary disease
      • - Pituitary insufficiency (tumours, radiation, surgery)
      • - Hyperprolactinaemia
      • - Exogenous hormones (anabolic steroids, glucocorticoid excess, hyper- or hypothyroidism)
  • Testicular:
    • Congenital

      Genetic

      • - Chromosomal (Kleinfelter syndrome 47, XXY)
      • - Y chromosome microdeletions
      • - Noonan syndrome (male Turner syndrome 45, XO)

      Other

      • - Cryptorchidism
    • Acquired
      • - Injury (orchitis, torsion, trauma)
      • - Varicocele
      • - Systemic disease (renal failure, liver failure)
      • - Chemotherapy, radiotherapy
      • - Testicular tumours
      • - Idiopathic
  • Post-testicular (obstruction):
    • Congenital
      • - Cystic fibrosis, congenital absence of the vas deferens (CAVD)
      • - Young's syndrome
    • Acquired
      • - Vasectomy
      • - Infection (chlamydia, gonorrhoea)
      • - Iatrogenic vasal injury
    • Disorders of sperm function or motility
      • - Immotile cilia syndrome
      • - Maturation defects
      • - Immunological infertility
      • - Globozoospermia
    • Sexual dysfunction
      • - Timing and frequency
      • - Erectile/ ejaculatory dysfunction
      • - Diabetes mellitus, multiple sclerosis, spinal cord/pelvic injuries

Regulation of spermatogenesis

  1. Top of page
  2. Abstract
  3. Introduction
  4. Epidemiology of male infertility
  5. Regulation of spermatogenesis
  6. Causes of male infertility
  7. Clinical management
  8. Investigations
  9. Treatment options
  10. Ethical issues
  11. Conclusion
  12. References

Sperm are formed in the seminiferous tubules, from germinal cells called spermatogonia. Spermatogonia divide by mitosis into primary spermatocytes, which in turn undergo two reduction divisions (meiosis I and II) to form spermatids. By the process of spermiogenesis, spermatids transform into mature cytoplasm-free sperm with condensed DNA in the head, an apical acrosome and a tail. Normal spermatogenesis is under the influence of follicular stimulating hormone (FSH) and testosterone. FSH binds to Sertoli cells and increases spermatogonial number and maturation to spermatocytes, but it is unable to complete spermatogenesis alone. Luteinising hormone (LH) is necessary for testosterone production by the Leydig cells, and plays an essential role in spermatid maturation. The entire spermatogenic process, including transit in the ductal testicular system takes approximately 3 months.[12] This is important to bear in mind when advising individuals on the potential effect of lifestyle changes on semen quality improvement.

Causes of male infertility

  1. Top of page
  2. Abstract
  3. Introduction
  4. Epidemiology of male infertility
  5. Regulation of spermatogenesis
  6. Causes of male infertility
  7. Clinical management
  8. Investigations
  9. Treatment options
  10. Ethical issues
  11. Conclusion
  12. References

Causes of male factor infertility can be classified into pretesticular, testicular and post-testicular (Box 1). Conditions that act at the pretesticular level tend to be hormonal in nature and most of these can be treated with hormone manipulation. Causes at the testicular level are largely irreversible, but can be treated with assisted reproductive technology (ART), if sperm is retrievable. Post-testicular causes can be treated with microsurgery or with ART. It is estimated that in about 50% of men with poor semen quality, no cause for this will be identified.[13]

Male age

Male age has been shown to have an impact on fertility and offspring health.[14] A UK study[15] has shown that paternal age of >35 years halves the chance of achieving a pregnancy compared with a paternal age of <25 years. The effect of age on male fertility is more noticeable after the age of 50,[16] with studies showing a concomitant increase in adverse outcome in the offspring.[17, 18] For this reason, the age of semen donors is limited to 40 or 45 years in some countries.[19]

Environmental, occupational and lifestyle factors

There is increasing evidence from epidemiological studies that occupational exposures to certain chemicals can affect semen quality.[20, 21] More than 104 000 such chemicals and physical agents have been identified.[1] These include heat, X-rays, heavy metals (lead, mercury), glycol ethers (highly volatile compounds used as solvents)[22] and pesticides; a well documented example being dibromochloropropane (DBCP),[21] a nematocide used in certain crops. The exact mechanism by which these occupational substances affect male fertility remains unclear.

Despite earlier reports, the level of environmental estrogens would not appear to be a threat to male reproductive health.[23] Recent observational studies support a dose-dependent decrease in semen parameters related to exposure to electromagnetic waves emitted from mobile phones.[24-26] The clinical significance of this, however, remains unclear. Testicular hyperthermia may affect semen quality.[27] However, there is no clear evidence that wearing loose-fitting underwear improves fertility.[1, 28, 29] There is evidence that a sedentary lifestyle, most likely through elevated scrotal temperature, can affect sperm production.[30]

Obesity is an important lifestyle factor that has been shown to be associated with poor semen quality.[31, 32] As the prevalence of obesity in Western countries is increasing, it is likely that it will have an increasing impact on male fertility. The mechanism by which obesity causes altered semen parameters is thought to be through an imbalance of reproductive hormone levels, as obese men have reduced sex hormone binding globulin and elevated estrogen levels. Altered metabolism of environmental toxins, sedentary lifestyle factors and increased risk of sexual dysfunction are also thought to contribute to reduced fertility in heavier men.[32]

Anabolic-androgenic steroids may induce azoospermia by interfering with the hypothalamo-pituitary-gonadal (HPG) axis. They may also inhibit male reproductive function through loss of libido and erectile dysfunction secondary to low endogenous testosterone levels. Azoospermia may be reversed by conservative management when the drugs are discontinued, especially in non-heavy users,[33, 34] or by administration of human chorionic gonadotrophin and human menopausal gonadotrophin.[35] Sperm quality tends to recover spontaneously within 4–12 months after discontinuation.[36] However, persistent alterations in semen parameters can remain even after cessation of use. It is therefore important to encourage discontinuation of use immediately and to emphasise that even ‘steroid-free’ dietary supplements have been reported to be contaminated with traces of hormones.[34]

Heavy alcohol consumption, but not moderate consumption, may affect sexual and reproductive performance in a reversible fashion.[1, 37] Tobacco smoking and cannabis consumption have been shown to reduce semen parameters, although the relationship between male smoking habits and fertility remains uncertain.[38] Although smokers in general may not experience reduced fertility, men with suboptimal semen quality may benefit from quitting smoking and this should be strongly encouraged. Other recreational drugs such as cocaine, amphetamines and opiates may adversely affect reproductive performance due to decreased libido and erectile dysfunction.[39]

According to some reports, sperm DNA damage secondary to oxidative stress may be the cause of between 30% and 80% of male subfertility cases.[40] Recent evidence suggests that antioxidant supplementation in subfertile males, including carnitines, vitamin C, vitamin E, selenium, zinc and coenzyme Q10, improves semen quality and live birth rates in couples undergoing fertility treatment.[40, 41]

Pretesticular

Hypogonadotrophic hypogonadism is rare and accounts for <1% of male factor fertility problems.[42] It results from decreased production of FSH and LH secondary to hypothalamic or pituitary dysfunction, which leads to failure of spermatogenesis and testosterone secretion by the testes. It may be congenital or acquired. Causes include craniopharyngiomas, surgery for pituitary tumours, head trauma, haemochromatosis, Kallmann syndrome and other congenital genetic syndromes of reduced gonadotrophin releasing hormone (GnRH) secretion (Prader–Willi syndrome, Laurence–Moon–Biedl syndrome).

Testicular

Hypergonadotrophic hypogonadism results from testicular failure and leads to oligozoospermia and non-obstructive azoospermia with elevated LH and FSH levels. Also, the finding of normal testosterone and LH levels with an elevated FSH implies isolated spermatogenic failure without Leydig cell damage. Causes of testicular failure include bilateral cryptorchidism, genetic disorders, systemic disease, radiotherapy or chemotherapy (see Box 1). However, in the majority of cases (66%) the cause is unknown.[1] The diagnosis is based on reduction in testicular size and elevation of serum FSH levels.

Varicocele

Varicoceles, a collection of dilated refluxing veins in the spermatic cord, are found in 11.7% of men with normal semen and 25.4% of men with abnormal semen.[1] The exact mechanism by which a varicocele can affect fertility is not well understood but theories include increased scrotal heating and altered testicular steroidogenesis.[43] The diagnostic significance of a varicocele is debatable.[44-46]

Post-testicular

Obstruction, excluding vasectomy, accounts for up to 41% of causes of azoospermia.[47] The diagnosis is based on normal serum FSH levels, normal testicular volume and evidence of complete spermatogenesis on biopsy. Causes include surgical trauma and vasectomy, infection (chlamydia, gonorrhoea, tuberculosis), and congenital bilateral absence of vas deferens (CBAVD).

Clinical management

  1. Top of page
  2. Abstract
  3. Introduction
  4. Epidemiology of male infertility
  5. Regulation of spermatogenesis
  6. Causes of male infertility
  7. Clinical management
  8. Investigations
  9. Treatment options
  10. Ethical issues
  11. Conclusion
  12. References

History and physical examination together with the semen analysis provide the basic information for the initial evaluation of most men.

Box 2. Components of infertility history in the male

Medical history

Recent pyrexia/ illness

Systemic illness – diabetes mellitus, cancer, infection

Genetic disorders – cystic fibrosis, Klinefelter syndrome

Surgical history

Undescended testes, orchidopexy

Hernia repair

Testicular trauma, torsion

Pelvic, bladder or retroperitoneal surgery

Fertility history

Previous pregnancies – with current and previous partners

Duration of infertility

Previous infertility treatments

Sexual history

Erection or ejaculation problems

Frequency of intercourse

Medication

Nitrofurantoin, cimetidine, sulfasalazine, spironolactone, α-blockers,

methotrexate, colchicine, amiodarone, antidepressants, phenothiazines, chemotherapy

Social history

Alcohol, smoking, anabolic steroids, recreational drugs

Exposure to ionising radiation

Chronic heat exposure

Aniline dyes

Pesticides

Lead exposure

History

In addition to a normal general medical history, particular attention should be paid to history of undescended testes, pubertal development, genital surgery or infection, fertility in the current or previous relationships and coital frequency, erection or ejaculation problems. A list of information relevant to the infertility history is summarised in Box  2.

Physical examination

Examination of the male is important to identify any general health issues associated with infertility. The general appearance should be noted, including any signs of decreased body hair or gynaecomastia suggestive of androgen deficiency. The height, weight, BMI and blood pressure should be noted.

The scrotum should be carefully palpated with the patient standing. Testicular size and consistency should be noted. If one or other testicle is impalpable, the groin should be examined to see if it can be located. The presence and normality of the vasa deferentia should be confirmed. For size measurement, an orchidometer can be used for volume estimation. A mean volume of 20 ml in the adult is considered normal.[47] Consistency can be described as firm (normal), soft or hard (abnormal). A soft or small testis can indicate impaired spermatogenesis. If an undescended testicle is diagnosed, the patient should be referred to a urologist for further management.

The epididymis should be examined for distension or induration. Engorgement of the pampiniform plexus of veins in the scrotum is indicative of a varicocele. Varicoceles are usually found on the left side and may be associated with atrophy of the left testis. Testicular size discrepancy and the feeling of a ‘bag of worms’ with a Valsalva manoeuvre should alert to this possibility. Varicoceles are best identified with the patient standing.

Penile and prostatic abnormalities may also be noted. Penile abnormalities such as micropenis or hypospadias may result in inadequate delivery of semen to the upper vagina. Rectal examination may reveal prostate abnormalities or seminal vesicle enlargement.

Investigations

  1. Top of page
  2. Abstract
  3. Introduction
  4. Epidemiology of male infertility
  5. Regulation of spermatogenesis
  6. Causes of male infertility
  7. Clinical management
  8. Investigations
  9. Treatment options
  10. Ethical issues
  11. Conclusion
  12. References

Semen analysis

Semen analysis is the most important investigation of male subfertility. This is not a test for fertility but a guide for minimal standards of adequacy. What constitutes a ‘normal’ result has been a matter of debate, and recently the WHO[48] normal ranges for semen parameters have changed (Table 1). These values represent the 5th percentile of semen characteristics of men initiating natural conception within 12 months of unprotected intercourse, in a number of different countries. It is important to remember that these are not absolute limits and should always be interpreted in conjunction with relevant clinical information to provide guidance about the prospects of a particular couple's fertility.

Table 1. World Health Organization reference limits and 95% confidence intervals for semen parameters[48]
ParameterReference limit95% confidence interval
  1. NP = non-progressive motility; PR = progressive motility

Semen volume (ml)1.51.4–1.7
Sperm concentration (106/ml)15.012–16
Total number (106/ejaculate)39.033–46
Total motility (PR+NP,%)40.038–42
Progressive motility (PR,%)32.031–34
Normal forms (%)4.03.0–4.0
Vitality (%)58.055–63

NICE[1] recommends that semen analysis should be performed according to the WHO methodology. This must be carried out in a qualified lab in accordance with the UK National External Quality Assessment Service (NEQAS) accreditation standards.[49] One sample will suffice if normal. However, a man's sperm count can vary considerably over time and therefore, if an abnormality is detected a repeat semen analysis should be performed after 3 months, or sooner if the initial test shows azoospermia. This reduces the likelihood of a transient illness causing misleading results.

It is important that clear instructions regarding the period of abstinence, method of production and transport of specimen to the laboratory is provided. With each day of sexual abstinence semen volume rises and sperm concentration increases. However sperm motility tends to fall with prolonged periods of abstinence of more than 5 days and therefore it is recommended that semen for analysis is collected after 72 hours. The entire ejaculate should be collected and the sample should be analysed within an hour of collection because sperm motility decreases after ejaculation. If produced at home, the sample should be kept at body temperature during transport.

Fresh semen is coagulated and liquefies 15–30 minutes after ejaculation. Low ejaculate volumes of <1.5 ml may not buffer against vaginal acidity sufficiently. This may indicate retrograde ejaculation, obstruction, androgen deficiency, incomplete collection or anejaculation.

Endocrine tests

Evaluation of the HPG axis can provide valuable information regarding sperm production. FSH, LH, testosterone and prolactin should be measured in men with sperm counts of <5 × 106 ml−1. Testosterone levels undergo diurnal variation; they are highest in the morning, and therefore random measurements should be interpreted with caution if the result is borderline. FSH reflects sperm production. Low testosterone levels with high FSH and LH indicate primary testicular failure whereas low testosterone levels in combination with low LH and FSH levels indicate a central defect with secondary hypogonadism. Azoospermia in combination with normal hormone levels suggests an obstructive cause.

Other indications for serum endocrinology testing include evidence of impaired sexual function (e.g. impotence, reduced libido) and clinical symptoms of endocrine disease (e.g. hypothyroidism).

Genetic evaluation

Subtle genetic abnormalities can present as male infertility. A karyotype is indicated in cases of severe oligospermia or azoospermia because these men are at increased risk of structural and sex-chromosomal anomalies. Klinefelter syndrome (47, XXY) is the most frequently detected sex chromosomal abnormality. As many as 10–15% of men with azoospermia and 5–10% of men with severe oligospermia have underlying micro-deletions in one or more gene regions implicated in spermatogenesis, on the long arm of the Y chromosome (Yq).[50] This region includes the Azoospermia Factor (AZF) locus, which contains three subregions: AZFa, AZFb, and AZFc. AZFc micro-deletions have a good prognosis for surgical sperm recovery whereas the prognostic value for sperm recovery in AZFa and AZFb micro-deletions is poor[51] and such individuals should not be offered surgical sperm retrieval. However, more studies are needed in this area to confirm the precise prognostic significance. CBAVD can be associated with cystic fibrosis carrier status and therefore men with non-palpable vas deferens should be tested for mutations in the cystic fibrosis gene, as indeed should all men with idiopathic obstructive azoospermia.

Imaging

Scrotal ultrasound should be performed if an abnormality such as a testicular tumour is detected on physical examination. Ultrasound can also be useful in the clinical diagnosis of varicocele, especially with the use of colour flow Doppler and demonstration of retrograde blood flow with a Valsalva manoeuvre. If an absent vas is detected on examination, a renal ultrasound scan is recommended, as up to 30% of such men may have a renal abnormality.[52]

Testicular biopsy

Testicular biopsy can aid the diagnosis of severe oligospermia and azoospermia and facilitate sperm recovery for intracytoplasmic sperm injection (ICSI) use. Biopsy can be done by an open or percutaneous needle approach and is used to obtain a small piece of testicular tissue for histological examination. Testicular biopsy specimens can be classified histologically:[53]

  • normal (appropriate number of cells with complete spermatogenesis)
  • hypospermatogenesis (all cell types present and in correct ratio but at reduced cell numbers)
  • maturation arrest (failure of spermatogenesis beyond a certain stage; can be ‘early’ or ‘late’)
  • sertoli cell-only (del Castillo) syndrome (no germ cells).

In some cases complex mixtures of pathological patterns may be present.

Other sperm function tests

Routine semen analysis provides information about spermatogenesis and sperm delivery, but gives little information about the functional ability of sperm. A number of tests have been developed to assess this.[54] These include the postcoital test, the sperm penetration assay (SPA) and the hemizona assay (HZA). There is some evidence to suggest that these tests can correlate with the outcome of natural conception or in vitro fertilisation (IVF), but the general consensus is that they are of limited value from a practical point of view.[1] They are therefore not used routinely in clinical practice in the UK.

Sperm DNA fragmentation has been shown to be a robust predictor of assisted reproductive outcomes.[55, 56] Sperm DNA tests such as the sperm chromatin structure assay (SCSA), the comet assay and the TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP nick end-labelling) assay, which assess sperm DNA integrity, show promise both as diagnostic tests for male infertility and prognostic tests for the outcome of assisted reproductive technologies.[57] Their clinical application, however, needs further evaluation and improvement.[55]

Treatment options

  1. Top of page
  2. Abstract
  3. Introduction
  4. Epidemiology of male infertility
  5. Regulation of spermatogenesis
  6. Causes of male infertility
  7. Clinical management
  8. Investigations
  9. Treatment options
  10. Ethical issues
  11. Conclusion
  12. References

Medical treatment

Specific hormonal treatments can be effective in known endocrine disorders such as hyperprolactinaemia, hypothyroidism and congenital adrenal hyperplasia. Hypogonadotrophic hypogonadism can be treated successfully with GnRH or exogenous gonadotrophins. In general though, medical treatments have a limited role in idiopathic male infertility.

Primary testicular failure

There is no effective treatment to restore fertility in primary testicular failure. Men undergoing treatments that contribute to infertility, such as chemotherapy, should be offered the opportunity to cryopreserve semen.[1] Alternatively, surgical sperm retrieval with assisted reproduction or donor sperm may be considered.[1]

Urological surgery

Reversal of vasectomy

The success rates for vasectomy reversal depend on the skill of the operating surgeon, surgical technique and the time from the initial surgery. Patency rates seem to decline with increasing time due to the increasing rates of anti-sperm antibody development and secondary epididymal obstruction.[58]

Surgical sperm retrieval

Sperm can be retrieved from the testes or the epididymis for use in IVF/ICSI. Common indications include obstructive causes, severe male factor infertility or ejaculatory failure. Techniques for sperm retrieval from the testes include testicular sperm aspiration (TESA), testicular sperm extraction (TESE) and microsurgical TESE (micro-TESE). The results of a single biopsy may not be indicative of the spermatogenic process in the whole of the testis and multiple biopsies may be necessary. Sperm from the epididymis can be retrieved by microsurgical (MESA) or percutaneous (PESA) epididymal sperm aspiration under local anaesthetic. Testicular biopsy should be done in a tertiary centre with facilities for sperm cryopreservation. Success rates for surgical sperm retrieval of almost 100% have been reported in obstructive cases, with lower rates of approximately 50% in non-obstructive cases. A meta-analysis of the use of surgical sperm retrieval in azoospermic men, showed the outcome of ICSI cycles in terms of fertilisation rates and clinical pregnancy rates to be significantly higher with the use of sperm from men with obstructive azoospermia as compared with non-obstructive azoospermia.[59]

Varicocele repair

The degree to which varicocele repair improves pregnancy rates and the success of assisted reproductive technology remains controversial. NICE[1] recommends that:

‘men should not be offered surgery for varicoceles as a form of fertility treatment because it does not improve pregnancy rates’.

However, recent evidence from a randomised control trial indicates that varicocelectomy in infertile men with impaired semen quality and palpable varicoceles, significantly improves semen characteristics and the chances of pregnancy within 1 year of follow-up.[60] Overall, the evidence is stronger with regard to an improvement in sperm parameters, with less convincing evidence for this translating into higher spontaneous pregnancy rates.[61] Varicocelectomy may also correct the serum testosterone deficit in men with varicocele and low testosterone levels.[62]

Assisted reproduction

Intrauterine insemination (IUI)

IUI involves the placement of a washed pellet of ejaculated sperm within the uterine cavity, thus bypassing the cervical barrier. It can be performed with or without ovarian stimulation. Indications include mild male factor infertility, immunologic infertility and mechanical problems of sperm delivery such as erectile dysfunction or hypospadias. NICE recommends that IUI is used in mild forms of oligozoospermia,[1] however, specific semen criteria for its use have not been standardised. Monthly conception rates of 8–16% have been reported[63] for IUI, however its efficacy has been questioned by recent studies.[64, 65] NICE[1] currently recommends the use of up to six cycles of unstimulated IUI in mild cases of male factor infertility in order to reduce the rate of multiple pregnancies.

In vitro fertilisation (IVF) and intracytoplasmic sperm injection (ICSI)

Although IVF can be used to treat milder forms of sperm abnormalities, more severe forms require ICSI. ICSI was originally described in 1988[66] and has since revolutionised the treatment of male factor infertility. It involves the micromanipulation and injection of a single human sperm into the cytoplasm of the oocyte. ICSI requires ovarian stimulation, oocyte retrieval and sperm preparation as for IVF. It is used for un-correctable severe forms of male factor infertility including oligospermia and asthenoteratozoospermia, or following fertilisation failure in a previous IVF cycle. Average pregnancy rates of 33.0% per embryo transfer have been reported after ICSI.[50, 67]

Ethical issues

  1. Top of page
  2. Abstract
  3. Introduction
  4. Epidemiology of male infertility
  5. Regulation of spermatogenesis
  6. Causes of male infertility
  7. Clinical management
  8. Investigations
  9. Treatment options
  10. Ethical issues
  11. Conclusion
  12. References

As ICSI bypasses the natural barriers to fertilisation, it raises one important matter of concern, which is the potential genetic risks associated with this procedure and the propagation of genetic defects that caused the infertility. This has ethical implications, especially with respect to the propagation of genetic defects that may re-surface in the male offspring of treatable infertile men. This could potentially lead to the creation of a population of subfertile men.

Recent data suggest that offspring born to infertile couples using ICSI have a higher incidence of chromosomal anomalies than do children who are naturally conceived.[50, 68, 69] This may relate to the characteristics of the couples that require such treatment. The relationship between ICSI and the risk of congenital abnormality in the offspring remains unclear. In view of these concerns, and until robust evidence is available, couples should be fully counselled about these uncertainties prior to initiating treatment.[1, 69]

‘Artificial’ haploid gametes have been successfully created in vitro from embryonic stem cells in animal models.[70, 71] These gametes have been used to create live offspring in mice.[72] The prospect of using artificially created human sperm to treat male fertility problems would raise important and far-reaching ethical issues.

Conclusion

  1. Top of page
  2. Abstract
  3. Introduction
  4. Epidemiology of male infertility
  5. Regulation of spermatogenesis
  6. Causes of male infertility
  7. Clinical management
  8. Investigations
  9. Treatment options
  10. Ethical issues
  11. Conclusion
  12. References

Male infertility is a common problem that requires appropriate specialist referral. Assessment should include full clinical history and careful examination. Semen analysis remains the main initial investigation that guides further assessment of the infertile male. Over the past two decades, advances in research have increased the treatment options available for male infertility. The potential for ICSI to propagate genetic abnormalities warrants thorough counselling for couples regarding the possible implications of its use, prior to treatment starting. The health and wellbeing of children following ICSI requires long-term follow-up.

In the future, a better understanding of the causes of male infertility and new reproductive technologies may offer the possibility of novel treatments, but these need to be carried out within the appropriate ethical framework.

Conflict of interest

None declared.

References

  1. Top of page
  2. Abstract
  3. Introduction
  4. Epidemiology of male infertility
  5. Regulation of spermatogenesis
  6. Causes of male infertility
  7. Clinical management
  8. Investigations
  9. Treatment options
  10. Ethical issues
  11. Conclusion
  12. References
  • 1
    National Collaborating Centre for Women's and Children's Health. Fertility: Assessment and Treatment for People with Fertility Problems. London: RCOG Press; 2004.
  • 2
    Hull MG, Glazener CM, Kelly NJ, Conway DI, Foster PA, Hinton RA, et al. Population study of causes, treatment, and outcome of infertility. BMJ 1985;291:16937.
  • 3
    Thonneau P, Marchand S, Tallec A, Ferial ML, Ducot B, Lansac J, et al. Incidence and main causes of infertility in a resident population (1,850,000) of three French regions (1988–1989). Hum Reprod 1991;6:8116.
  • 4
    Human Fertilisation and Embryology Authority. Fertility Treatment in 2010 – Trends and Figures. London: HFEA; 2010 [http://www.hfea.gov.uk./docs/2011-11-16_-_Annual_Register_Figures_Report_final.pdf].
  • 5
    Macleod J. Semen quality in 1000 men of known fertility and in 800 cases of infertile marriage. Fertil Steril 1951;2:11539.
  • 6
    Carlsen E, Giwercman A, Keiding N, Skakkebaek N. Evidence for decreasing quality of semen during past 50 years. BMJ 1992;305:60913.
  • 7
    Joffe M. What has happened to human fertility. Hum Reprod 2010;25:295307.
  • 8
    Povey AC, Stocks SJ. Epidemiology and trends in male subfertility. Human Fertility 2010;13(4):1828.
  • 9
    Human Fertilisation and Embryology Authority. A Long Term Analysis of the HFEA Register Data (1991–2006). London: HFEA; 2007 [http://www.hfea.gov.uk/docs/Latest_long_term_data_analysis_report_91-06.pdf].
  • 10
    Skakkebaek NE, Rajpert-De Meyts E, Main KM. Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects. Hum Reprod 2001;16:9728.
  • 11
    Akre O, Richiardi L. Does a testicular dysgenesis syndrome exist? Hum Reprod 2009;24:205360.
  • 12
    Alukal JP, Lamb DJ, Niederberger CS, Makhlouf AA. Spermatogenesis in the adult. In: Lipshultz LI, Howards SS, Niederberger CS, editors. Infertility in the Male. 4th ed. Cambridge: Cambridge University Press; 2009. p. 7489.
  • 13
    Balen AH. Male factor infertility. In: Infertility in Practice. 3rd ed. London: Informa Healthcare; 2008 p. 25878.
  • 14
    Royal College of Obstetricians and Gynaecologists. Reproductive Ageing. SAC Opinion Paper 24. London: RCOG; 2011.
  • 15
    Ford WC, North K, Taylor H, Farrow A, Hull MG, Golding J. Increasing paternal age is associated with delayed conception in a large population of fertile couples: evidence for declining fecundity in older men. The ALSPAC study team (Avon longitudinal study of pregnancy and childhood). Hum Reprod 2000;15:17038.
  • 16
    Practice Committee of American Society for Reproductive Medicine in collaboration with Society for Reproductive Endocrinology and Infertility. Optimising natural fertility. Fertil Steril 2008; 90:S16.
  • 17
    Baird DT, Collins J, Egozcue J, Evers LH, Gianaroli L, Leridon H, et al. Fertility and ageing. Human Reprod Update 2005;11:26176.
  • 18
    Eskenazi B, Wyrobek AJ, Sloter E, Kidd SA, Moore L, Young S, et al. The association of age and semen quality in healthy men. Human Reprod 2003;18:44754.
  • 19
    Association of Biomedical Andrologists, Association of Clinical Embryologists, British Andrology Society, British Fertility Society, Royal College of Obstetricians and Gynaecologists. UK guidelines for the medical and laboratory screening of sperm, egg and embryo donors (2008). Hum Fertil 2008; 11:20110.
  • 20
    Jurewicz J, Hanke W, Radwan M, Bonde JP. Environmental factors and semen quality. Int J Occup Med Environ Health 2009;22:30529.
  • 21
    Sharpe RM. Environmental/lifestyle effects on spermatogenesis. Philos Trans R Soc Lond B Biol Sci 2010;365:1697712.
  • 22
    Cherry N, Moore H, McNamee R, Pacey A, Burgess G, Clyma JA, et al. Occupation and male infertility: glycol ethers and other exposures. Occup Environ Med 2008;65:70814.
  • 23
    Toppari J, Larsen JC, Christiansen P, Giwercman A, Grandjean P, Guillette LJ Jr, et al. Male reproductive health and environmental xenoestrogens. Environ Health Perspect 1996;104(Suppl 4):741803.
  • 24
    Agarwal A, Deepinder F, Sharma RK, Ranga G, Li J. Effect of cell phone usage on semen analysis in men attending infertility clinic: an observational study. Fertil Steril 2008;89:1248.
  • 25
    Erogul O, Oztas E, Yildirum I, Kir T, Aydur E, Komesli G, et al. Effects of electromagnetic radiation from a cellular phone on human sperm motility: an in vitro study. Arch Med Res 2006;37:8403.
  • 26
    Wdowiak A, Wdowiak L, Wiktor H. Evaluation of the effect of using mobile phones on male fertility. Ann Agric Environ Med 2007;14:16972.
  • 27
    Mieusset R, Bujan L. Testicular heating and its possible contributions to male infertility: a review. Int J Androl 1995;18:16984.
  • 28
    Tiemessen CH, Evers JL, Bots RS. Tight-fitting underwear and sperm quality. Lancet 1996;347:18445.
  • 29
    Munkelwitz R, Gilbert BR. Are boxer shorts really better? A critical analysis of the role of underwear type in male subfertility. J Urol 1998;160:132933.
  • 30
    Magnusdottir EV, Thorsteinsson T, Thorsteinsdottir S, Heimisdottir M, Olafsdottir K. Persistent organochlorines, sedentary occupation, obesity and human male subfertility. Hum Reprod 2005;20(1):20815.
  • 31
    Sharpe RM, Franks S. Environment, lifestyle and infertility – an inter-generational issue. Nat Cell Biol 2002;4(Suppl):S3340.
  • 32
    Hammoud AO, Gibson M, Peterson CM, Meikle AW, Carrell DT. Impact of male obesity on infertility: a critical review of the current literature. Fertil Steril 2008;90:897904.
  • 33
    Gazvani MR, Buckett W, Luckas MJ, Aird IA, Hipkin LJ, Lewis-Jones DI. Conservative management of azoospermia following steroid abuse. Hum Reprod 1997;12:17068.
  • 34
    de Souza GL, Hallak J. Anabolic steroids and male infertility: a comprehensive review. BJU Int 2011;108:18605.
  • 35
    Menon DK. Successful treatment of anabolic steroid-induced azoospermia with human chorionic gonadotropin and human menopausal gonadotropin. Fertil Steril 2003;79(Suppl 3):165961.
  • 36
    Turek PJ, Williams RH, Gilbaugh JH III, Lipshultz LI. The reversibility of anabolic steroid-induced azoospermia. J Urol 1995;153:162830.
  • 37
    Buffum J. Pharmacosexology: the effects of drugs on sexual function- a review. J Psychoactive Drugs 1982;14:544.
  • 38
    Vine MF. Smoking and male reproduction: a review. Int J Androl 1996;19:32337.
  • 39
    Nudell DM, Monoski MM, Lipshultz Li. Common medications and drugs: how they affect male fertility. Urol Clin North Am 2002;29:96573.
  • 40
    Showell MG, Brown J, Yazdani A, Stankiewicz MT, Hart RJ. Antioxidants for male subfertility. Cochrane Database Syst Rev 2011; (1):CD007411.
  • 41
    Agarwal A, Sekhon L. The role of antioxidant therapy in the treatment of male infertility. Hum Fertil (Camb) 2010;13:21725.
  • 42
    Jarow JP, Espeland MA, Lipshultz LI. Evaluation of the azoospermic patient. J Urol 1989;142:625.
  • 43
    Marmar JL. The pathophysiology of varicoceles in the light of current molecular and genetic information. Hum Reprod Update 2001;7:46172.
  • 44
    Evers JH, Collins J, Clarke J. Surgery or embolisation for varicoceles in subfertile men. Cochrane Database Syst Rev 2009;(1):CD000479.
  • 45
    Nevoux P, Mitchell V, Chevallier D, Rigot JM, Marcelli F. Varicocele repair: does it still have a role in infertility treatment? Curr Opin Obstet Gynecol 23:1517.
  • 46
    Polito M Jr, Muzzonigro G, Centini R, Candelari R, Antico E, Boscaro M, et al. Percutaneous therapy of varicocele: effects on semen parameters in young adults. Urol Int 2004;72:1503.
  • 47
    Sigman M, Lipshultz LI, Howards SS. Office evaluation of the subfertile male. In: Lipshultz LI, Howards SS, Neiderberger CS, editors. Infertility in the Male. 4th ed. Cambridge: Cambridge University Press; 2009. p. 15376.
  • 48
    Cooper TG, Noonan E, von Eckardstein S, Auger J, Baker HW, Behre HM, et al. World Health Organization reference values for human semen characteristics. Hum Reprod Update 2010;16:23145.
  • 49
    United Kingdom National External Quality Assessment Service (UK NEQAS). Reproductive Science Semen Analysis [http://www.ukneqas.org.uk/content/PageServer.asp?S=784492418&C=1252&Type=N&AID=16&SID=3].
  • 50
    Royal College of Obstetricians and Gynaecologists. Perinatal Risks Associated with IVF. Scientific Impact Paper No 8. London: RCOG; 2007.
  • 51
    Oates RD, Lamb DJ. Genetic aspects of infertility. In: Lipshultz LI, Howards SS, Neiderberger CS, editors. Infertility in the Male. 4th ed. Cambridge: Cambridge University Press, 2009. p. 25176.
  • 52
    Honig S, Lamont J, Oates RD. Ultrasonographic renal and seminal vesicle abnormalities in patients with congenital absence of the vas deferens. J Urol 1991;145:453.
  • 53
    Cerilli LA, Kuang W, Rogers D. A practical approach to testicular biopsy interpretation for male infertility. Arch Pathol Lab Med 2010;134:1197204.
  • 54
    Aitken RJ. Sperm function tests and fertility. Int J Androl 2006;29:6975.
  • 55
    Barratt CL, Aitken RJ, Björndahl L, Carrell DT, de Boer P, Kvist U, et al. Sperm DNA: organization, protection and vulnerability: from basic science to clinical applications-a position report. Hum Reprod 2010;25:82438.
  • 56
    Simon L, Brunborg G, Stevenson M, Lutton D, McManus J, Lewis SE. Clinical significance of sperm DNA damage in assisted reproduction outcome. Hum Reprod 2010;25:1594608.
  • 57
    Lewis SE, Simon L. Clinical implications of sperm DNA damage. Hum Fertil (Camb) 2010;13:2017.
  • 58
    Belker AM, Thomas AJ, Fuchs EF, Konnak JW, Sharlip ID. Results of 1,469 microsurgical vasectomy reversals by the vasovasostomy study Group. J Urol 1991;145:50511.
  • 59
    Nicopoullos JD, Gilling-Smith C, Almeida PA, Norman-Taylor J, Grace I, Ramsay JW. Use of surgical sperm retrieval in azoospermic men: a meta-analysis. Fertil Steril 2004;82:691701.
  • 60
    Abdel-Meguid TA, Al-Sayyad A, Tayib A, Farsi HM. Does varicocele repair improve male infertility? An evidence-based perspective from a randomized, controlled trial. Eur Urol 2011;59:45561.
  • 61
    Baazeem A, Belzile E, Ciampi A, Dohle G, Jarvi K, Salonia A, et al. Varicocele and male factor infertility treatment: a new meta-analysis and review of the role of varicocele repair. Eur Urol 2011;60:796808.
  • 62
    Tanrikut C, McQuaid JW, Goldstein M. The impact of varicocele and varicocele repair on serum testosterone. Curr Opin Obstet Gynecol 2011;23:22731.
  • 63
    European Society of Human Reproduction and Embryology. ART Fact Sheet [http://www.eshre.eu/ESHRE/English/Guidelines-Legal/ART-fact-sheet/page.aspx/1061].
  • 64
    Bhattacharya S, Harrild K, Mollison J, Wordsworth S, Tay C, Harrold A, et al. Clomifene citrate or unstimulated intrauterine insemination compared with expectant management for unexplained infertility: pragmatic randomised controlled trial. BMJ 2008;337:a716.
  • 65
    Steures P, van der Steeg JW, Hompes PG, Bossuyt PM, van der Veen F, Habbema JD, et al. Intra-uterine insemination with controlled ovarian hyperstimulation compared to an expectant management in couples with unexplained subfertility and an intermediate prognosis: a randomised study. Ned Tijdschr Geneeskd 2008;152:152531.
  • 66
    Lazendorf SE, Malony MK, Veek LL, Slusser J, Hodgen GD, Rosenwaks Z. A preclinical evaluation of pronuclear formation by microinjection of human spermatozoa into human oocytes. Fertil Steril 1988;49:83542.
  • 67
    de Mouzon J, Goossens V, Bhattacharya S, Castilla JA, Ferraretti AP, Korsak V. European IVF-monitoring (EIM) Consortium, for the European Society of Human Reproduction and Embryology (ESHRE). Assisted reproductive technology in Europe, 2006: results generated from European registers by ESHRE. Hum Reprod 2010;25:185162.
  • 68
    Belva F, Henriet S, Liebaers I, Van Steirteghem A, Celestin-Westreich S, Bonduelle M. Medical outcome of 8-year-old singleton ICSI children (born >32 weeks gestation) and a spontaneously conceived comparison group. Hum Reprod 2007;22:50615.
  • 69
    Practice Committee of the American Society for Reproductive Medicine, Practice Committee of the Society for Assisted Reproductive Technology. Genetic considerations related to intracytoplasmic sperm injection (ICSI). Fert Steril 2008;90:S18284
  • 70
    Lokman M, Moore H. An artificial sperm – next year or never? Human Fertil (Camb) 2010;13:2726.
  • 71
    Sato T, Katagiri K, Gohbara A, Inoue K, Ogonuki N, Ogura A, et al. In vitro production of functional sperm in cultured neonatal mouse testes. Nature 2011;471:5047.
  • 72
    Nayernia K, Nolte J, Michelmann HW, Lee JH, Rathsack K, Drusenheimer N, et al. In vitro-differentiated embryonic stem cells give rise to male gametes that can generate offspring mice. Dev Cell 2006;11:12532.